The OIG’s recent Advisory Opinion suggest that under certain circumstances patient co-pay reimbursement programs are allowable. This article examines that opinion and highlights the types of controls that are likely needed.
Pharmaceutical companies have struggled with product messaging for years. With more and more healthcare professionals (HCPs) becoming “no see” HCPs, the companies have turned to the ultimate consumer of their product – patients. At the same time, insurers are asking patients directly to shoulder more of the healthcare costs by raising their co-pays and deductibles.
Read Full Article in the October 2016 Issue of Life Science Compliance Update